You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Details for Patent: 8,202,535

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,202,535 protect, and when does it expire?

Patent 8,202,535 protects DSUVIA and is included in one NDA.

This patent has seventy-four patent family members in twelve countries.

Summary for Patent: 8,202,535

Scope and claims summary:

Title:	Small-volume oral transmucosal dosage forms
Abstract:	Small-volume oral transmucosal dosage forms or NanoTabs.RTM. comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs.RTM. to administer a drug for the treatment of acute, post-operative or breakthrough pain.
Inventor(s):	Palmer; Pamela (San Francisco, CA), Schreck; Thomas (Portola Valley, CA), Tzannis; Stelios (Newark, CA), Hamel; Larry (Mountain View, CA), Poutiatine; Andrew I. (San Anselmo, CA)
Assignee:	Acelrx Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:	11/650,174
Patent Claim Types: see list of patent claims	Use; Delivery; Device; Dosage form;

Drugs Protected by US Patent 8,202,535

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertical Pharms	DSUVIA	sufentanil citrate	TABLET;SUBLINGUAL	209128-001	Nov 2, 2018		RX	Yes	Yes	8,202,535	⤷ Subscribe				TREATMENT OF ACUTE PAIN	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,202,535

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2114383	⤷ Subscribe	300797	Netherlands	⤷ Subscribe
European Patent Office	2114383	⤷ Subscribe	CA 2016 00007	Denmark	⤷ Subscribe
European Patent Office	2114383	⤷ Subscribe	CR 2016 00007	Denmark	⤷ Subscribe
European Patent Office	2114383	⤷ Subscribe	122016000023	Germany	⤷ Subscribe
European Patent Office	2114383	⤷ Subscribe	16C0010	France	⤷ Subscribe
European Patent Office	2114383	⤷ Subscribe	SPC/GB16/004	United Kingdom	⤷ Subscribe
Austria	E474564	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.